PAPER Lincoln KM, Richardson TE, Rutter L, Gonzalez P, Simpkins JW, Green KN
SEARCH RESULTS
229120 RESULTS
PAPER Lindsley CW
Alzheimer's disease: development of disease-modifying treatments is the challenge for our generation.
ACS Chem Neurosci. 2012 Nov 21;3(11):804-5. PubMed.PAPER Matveeva EG, Rudolph A, Moll JR, Thompson RB
Structure-selective anisotropy assay for amyloid Beta oligomers.
ACS Chem Neurosci. 2012 Nov 21;3(11):982-7. PubMed.PAPER Morales-Garcia JA, Luna-Medina R, Alonso-Gil S, Sanz-Sancristobal M, Palomo V, Gil C, Santos A, Martinez A, Perez-Castillo A
Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo.
ACS Chem Neurosci. 2012 Nov 21;3(11):963-71. PubMed.PAPER Naldi M, Fiori J, Pistolozzi M, Drake AF, Bertucci C, Wu R, Mlynarczyk K, Filipek S, De Simone A, Andrisano V
Amyloid β-Peptide 25-35 Self-Assembly and Its Inhibition: A Model Undecapeptide System to Gain Atomistic and Secondary Structure Details of the Alzheimer's Disease Process and Treatment.
ACS Chem Neurosci. 2012 Nov 21;3(11):952-62. PubMed.PAPER Smith B, Medda F, Gokhale V, Dunckley T, Hulme C
Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer's?
ACS Chem Neurosci. 2012 Nov 21;3(11):857-72. PubMed.PAPER Soper JH, Sugiyama S, Herbst-Robinson K, James MJ, Wang X, Trojanowski JQ, Smith AB, Lee VM, Ballatore C, Brunden KR
Brain-Penetrant Tetrahydronaphthalene Thromboxane A2-Prostanoid (TP) Receptor Antagonists as Prototype Therapeutics for Alzheimer's Disease.
ACS Chem Neurosci. 2012 Nov 21;3(11):928-40. PubMed.PAPER Tarr JC, Turlington ML, Reid PR, Utley TJ, Sheffler DJ, Cho HP, Klar R, Pancani T, Klein MT, Bridges TM, Morrison RD, Blobaum AL, Xiang Z, Daniels JS, Niswender CM, Conn PJ, Wood MR, Lindsley CW
Targeting Selective Activation of M(1) for the Treatment of Alzheimer's Disease: Further Chemical Optimization and Pharmacological Characterization of the M(1) Positive Allosteric Modulator ML169.
ACS Chem Neurosci. 2012 Nov 21;3(11):884-95. PubMed.PAPER Velasco PT, Heffern MC, Sebollela A, Popova IA, Lacor PN, Lee KB, Sun X, Tiano BN, Viola KL, Eckermann AL, Meade TJ, Klein WL
Synapse-Binding Subpopulations of Aβ Oligomers Sensitive to Peptide Assembly Blockers and scFv Antibodies.
ACS Chem Neurosci. 2012 Nov 21;3(11):972-81. PubMed.PAPER Cukalevski R, Boland B, Frohm B, Thulin E, Walsh D, Linse S
Role of aromatic side chains in amyloid β-protein aggregation.
ACS Chem Neurosci. 2012 Dec 19;3(12):1008-16. PubMed.PAPER Cochet M, Donneger R, Cassier E, Gaven F, Lichtenthaler SF, Marin P, Bockaert J, Dumuis A, Claeysen S
5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10.
ACS Chem Neurosci. 2013 Jan 16;4(1):130-40. PubMed.PAPER Coskuner O, Wise-Scira O, Perry G, Kitahara T
The structures of the E22Δ mutant-type amyloid-β alloforms and the impact of E22Δ mutation on the structures of the wild-type amyloid-β alloforms.
ACS Chem Neurosci. 2013 Feb 20;4(2):310-20. PubMed.PAPER Limapichat W, Yu WY, Branigan E, Lester HA, Dougherty DA
Key Binding Interactions for Memantine in the NMDA Receptor.
ACS Chem Neurosci. 2013 Feb 20;4(2):255-60. PubMed.PAPER Morales-García JA, Susín C, Alonso-Gil S, Pérez DI, Palomo V, Pérez C, Conde S, Santos A, Gil C, Martínez A, Pérez-Castillo A
Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.
ACS Chem Neurosci. 2013 Feb 20;4(2):350-60. PubMed.PAPER More SS, Vartak AP, Vince R
Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimer's disease.
ACS Chem Neurosci. 2013 Feb 20;4(2):330-8. PubMed.Current Filters
- TYPE: Paper x